相关实验视频

Updated: Jan 13, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

质谱学足迹显示了微小CYP2A6的结构变化,这些变化是由其减少酶黄 mononucleotide域的相互作用引起的

Mengqi Chai¹, Sarah D Burris-Hiday², Don L Rempel¹

¹Department of Chemistry, Washington University in St. Louis, St. Louis, Missouri.

Drug metabolism and disposition: the biological fate of chemicals

|January 6, 2026

概括

在NADPH细胞染色体P450还原酶的flavin单核酸域诱导CYP2A6的结构变化,这表明它在药物代谢中除了电子转移之外,还充当一个全osteric调节器.

科学领域:

生物化学生物化学
酶学是一种酶学.
药物新陈代谢药物新陈代谢

背景情况:

在药物代谢中,NADPH细胞P450减少酶 (CPR) 对人类细胞P450 (CYP) 酶活性至关重要.
CPR的flavin mononucleotide含有域 (FMND) 通常与CYP结合,以促进催化过程中的电子转移.
精确的CPR相互作用机制和超越电子转移的潜在调节作用仍然是研究领域.

研究的目的:

调查CYP2A6在与CPR的FMND相互作用时发生的结构变化.
为了比较单独CYP2A6与FMND融合的表面可访问性.
为了确定CPR的FMND是否通过全调节影响CYP2A6结构.

主要方法:

使用了三种基于质谱的足迹技术:-交换,化标记和蛋白质的快速光化学氧化 (FPOP).
将CYP2A6与融合蛋白 (FMND/CYP2A6) 的表面标记模式进行比较.
分析了氨基酸残留的差异性保护以推断结构变化.

主要成果:

在预期的CYP2A6.6的FMND结合部位上没有观察到差异性保护.
在FMND.的存在下,对CYP2A6表面残留物持续观察到增加的暴露.
这些发现表明FMND引起的CYP2A6显著的结构变化.

结论:

CPR的flavin mononucleotide域诱导CYP2A6结构的长距离全调节.
结构证据支持CPR作为电子捐赠者和P450酶的全调节器的双重作用.
这些发现提高了对药物代谢中复杂的调节机制的理解.

关键词:

化的足迹是因为化的存在.细胞染色体P450 2A6 (CYP2A6) 是一种蛋白质的快速光化学氧化.与的交换方式质谱足迹测量质谱足迹测量在NADPH-cytochrome P450降解酶中.

更多相关视频

In Vivo Hydroxyl Radical Protein Footprinting for the Study of Protein Interactions in Caenorhabditis elegans

In Vivo Hydroxyl Radical Protein Footprinting for the Study of Protein Interactions in Caenorhabditis elegans

Published on: April 1, 2020

Resin-Assisted Capture Coupled with Isobaric Tandem Mass Tag Labeling for Multiplexed Quantification of Protein Thiol Oxidation

Resin-Assisted Capture Coupled with Isobaric Tandem Mass Tag Labeling for Multiplexed Quantification of Protein Thiol Oxidation

Published on: June 21, 2021

相关概念视频

Drug Metabolism: Phase I Reactions

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...

Phase I Reactions: Reductive Reactions

Phase I Reactions: Reductive Reactions

Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...

Drug Metabolism: Phase II Reactions

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...